NO2644698T3 - - Google Patents

Info

Publication number
NO2644698T3
NO2644698T3 NO11842145A NO11842145A NO2644698T3 NO 2644698 T3 NO2644698 T3 NO 2644698T3 NO 11842145 A NO11842145 A NO 11842145A NO 11842145 A NO11842145 A NO 11842145A NO 2644698 T3 NO2644698 T3 NO 2644698T3
Authority
NO
Norway
Application number
NO11842145A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2644698T3 publication Critical patent/NO2644698T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetically Actuated Valves (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO11842145A 2010-11-17 2011-11-17 NO2644698T3 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010257022 2010-11-17
PCT/JP2011/076486 WO2012067176A1 (ja) 2010-11-17 2011-11-17 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子

Publications (1)

Publication Number Publication Date
NO2644698T3 true NO2644698T3 (pt) 2018-06-02

Family

ID=46084097

Family Applications (3)

Application Number Title Priority Date Filing Date
NO11842145A NO2644698T3 (pt) 2010-11-17 2011-11-17
NO2018024C NO2018024I1 (no) 2010-11-17 2018-07-10 Emicizumab (beskyttet av kravene 1 til 4 og 9 til 12 av patentet - tilsvarer antistoffet i krav 4(s)
NO2023034C NO2023034I1 (no) 2010-11-17 2023-09-06 Emicizumab

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2018024C NO2018024I1 (no) 2010-11-17 2018-07-10 Emicizumab (beskyttet av kravene 1 til 4 og 9 til 12 av patentet - tilsvarer antistoffet i krav 4(s)
NO2023034C NO2023034I1 (no) 2010-11-17 2023-09-06 Emicizumab

Country Status (29)

Country Link
US (9) US9334331B2 (pt)
EP (2) EP2644698B1 (pt)
JP (8) JP6013915B2 (pt)
KR (4) KR101962483B1 (pt)
CN (2) CN103298937B (pt)
AU (2) AU2011330184B2 (pt)
BR (1) BR112013012213A2 (pt)
CA (1) CA2817964C (pt)
DK (1) DK2644698T3 (pt)
ES (1) ES2660151T3 (pt)
FR (1) FR18C1031I2 (pt)
HK (1) HK1223379A1 (pt)
HR (1) HRP20180421T1 (pt)
HU (2) HUE038305T2 (pt)
LT (2) LT2644698T (pt)
LU (1) LUC00076I2 (pt)
MX (1) MX355060B (pt)
MY (1) MY166429A (pt)
NL (1) NL300940I2 (pt)
NO (3) NO2644698T3 (pt)
PH (1) PH12016502073A1 (pt)
PL (1) PL2644698T3 (pt)
PT (1) PT2644698T (pt)
RS (1) RS57038B1 (pt)
RU (3) RU2620071C2 (pt)
SI (1) SI2644698T1 (pt)
TR (1) TR201802772T4 (pt)
TW (4) TWI629355B (pt)
WO (1) WO2012067176A1 (pt)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578397B1 (en) * 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
EP3345607B1 (en) 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
DK2129396T3 (da) * 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
HUE029635T2 (en) * 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR
SG193868A1 (en) 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
BR112012017124C1 (pt) * 2009-12-25 2021-08-31 Chugai Pharmaceutical Co Ltd Método para produzir e para purificar um multímero polipeptídico
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
DK3195880T3 (da) * 2010-05-14 2020-03-02 Amgen Inc Højkoncentrerede anti-sclerostin-antistofformuleringer
US20110311547A1 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis Treatment
RU2620071C2 (ru) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
TW202323302A (zh) * 2010-11-30 2023-06-16 日商中外製藥股份有限公司 細胞傷害誘導治療劑
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
KR102168733B1 (ko) 2011-10-31 2020-10-23 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
CA3202536A1 (en) 2012-05-10 2013-11-14 Bioatla, Llc Multi-specific monoclonal antibodies
EP3590537A1 (en) * 2012-09-26 2020-01-08 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
TWI609083B (zh) 2012-09-28 2017-12-21 Chugai Pharmaceutical Co Ltd Blood coagulation reaction assessment method
US9708404B2 (en) * 2012-12-21 2017-07-18 Seattle Genetics, Inc. Anti-NTB-A antibodies and related compositions and methods
US11161906B2 (en) * 2013-07-25 2021-11-02 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2015069865A1 (en) * 2013-11-06 2015-05-14 Janssen Biotech, Inc. Anti-ccl17 antibodies
US11072647B2 (en) * 2013-12-19 2021-07-27 Onsejo Nacional DE Investigation Cientiticay Tecnica TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
EP4071177A1 (en) * 2013-12-30 2022-10-12 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2015120138A2 (en) * 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
PT3122775T (pt) * 2014-03-26 2019-12-26 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
CN105294857B (zh) * 2014-06-18 2019-02-19 上海交通大学 基于fix的抗原表位及其应用
JP6910800B2 (ja) * 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
TWI831106B (zh) * 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CA2955084C (en) * 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
US20170362304A1 (en) 2014-08-20 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
TWI700300B (zh) * 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) * 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
AU2015344769B2 (en) * 2014-11-12 2020-07-09 Allogene Therapeutics, Inc. Inhibitory chimeric antigen receptors
US10849862B2 (en) * 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
TWI703156B (zh) 2015-01-30 2020-09-01 學校法人埼玉醫科大學 抗ａｌｋ２抗體
EP3253778A1 (en) 2015-02-05 2017-12-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
AU2016219772A1 (en) * 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
LT3277717T (lt) * 2015-03-31 2021-08-10 Medimmune Limited Nauja il33 forma, mutuotos il33 formos, antikūnai, jų naudojimo testai ir būdai
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
CN107454906B (zh) * 2015-04-17 2022-05-27 豪夫迈·罗氏有限公司 使用凝固因子和多特异性抗体的联合治疗
JP2018123055A (ja) * 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
JP6147945B2 (ja) * 2015-04-24 2017-06-14 公立大学法人奈良県立医科大学 血液検体の凝固能の評価方法、並びにその方法に用いるための試薬、試薬キット及び装置
MX2017015380A (es) 2015-05-29 2018-03-28 Amphivena Therapeutics Inc Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
JP6823596B2 (ja) 2015-07-31 2021-02-03 中外製薬株式会社 アニオン性ポリマーによる抗体を含有する組成物の精製方法
KR101920175B1 (ko) 2015-09-18 2018-11-19 추가이 세이야쿠 가부시키가이샤 Il-8에 결합하는 항체 및 그의 사용
MX2018005720A (es) * 2015-11-17 2018-11-09 Suzhou Suncadia Biopharmaceuticals Co Ltd Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
EP3395835B1 (en) * 2015-12-25 2021-02-03 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
CA3011092A1 (en) * 2016-01-12 2017-07-20 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
CN113372446A (zh) * 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP3471759A1 (en) * 2016-06-15 2019-04-24 Novartis AG Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
HRP20240603T1 (hr) 2016-07-01 2024-07-19 Resolve Therapeutics, Llc Optimizirane fuzije binukleaze i postupci njihove upotrebe
CA3030765A1 (en) * 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
WO2018045130A1 (en) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
CN109661241A (zh) 2016-09-06 2019-04-19 中外制药株式会社 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
DK3515478T3 (da) * 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
US20190248920A1 (en) * 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
MX2019005397A (es) 2016-11-08 2019-10-09 Regeneron Pharma Proteinas de union a antigeno que antagonizan el receptor de leptina.
CA3044574A1 (en) * 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
KR20190096409A (ko) * 2016-12-21 2019-08-19 메레오 바이오파마 3 리미티드 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
US11680101B2 (en) * 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
CA3051639A1 (en) 2017-02-01 2018-08-09 Novo Nordisk A/S Procoagulant antibodies
CA3053231A1 (en) * 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN110869046A (zh) * 2017-03-31 2020-03-06 塞勒克提斯公司 通用型抗cd22嵌合抗原受体工程化的免疫细胞
TW201836636A (zh) * 2017-03-31 2018-10-16 公立大學法人奈良縣立醫科大學 含有替代凝血因子ｖｉｉｉ功能之多特異性抗原結合分子之用於預防和／或治療凝血因子ｉｘ異常症的醫藥組合物
KR20240135066A (ko) * 2017-04-13 2024-09-10 사이로파 비.브이. 항-sirp 알파 항체
UY37747A (es) * 2017-05-26 2019-01-02 Glaxosmithkline Ip Dev Ltd Composiciones para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados
CA3064298A1 (en) * 2017-06-01 2018-12-06 Shanghai Hengrui Pharmaceutical Co., Ltd. Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
TWI726228B (zh) * 2017-08-09 2021-05-01 國立臺灣大學 Ｃｄ１４拮抗分子用於治療癌症
JP2020531438A (ja) * 2017-08-16 2020-11-05 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、およびｅｇｆｒ、ｈｌａ−ｅ、ｃｃｒ４、またはｐｄ−ｌ１に結合するタンパク質
CN111315767A (zh) 2017-08-22 2020-06-19 萨纳生物有限责任公司 可溶性干扰素受体及其用途
JP7226833B2 (ja) * 2017-09-21 2023-02-21 イムチェック セラピューティクス エスエーエス Ｂｔｎ２に特異性を有する抗体及びその使用
UA128389C2 (uk) * 2017-09-29 2024-07-03 Чугаі Сейяку Кабусікі Кайся Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
CA3079053A1 (en) * 2017-11-01 2019-05-09 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
MA50893A (fr) * 2017-11-15 2020-09-23 Novo Nordisk As Liants de facteur x renforçant l'activation fx
WO2019104157A1 (en) * 2017-11-21 2019-05-31 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
BR112020012011A2 (pt) 2017-12-18 2020-11-24 Regeneron Pharmaceuticals, Inc. moléculas de ligação a antígeno biespecífica isolada e de ligação a antígeno biespecífica ou cadeia de imunoglobulina, composição farmacêutica, recipiente ou dispositivo de injeção, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, métodos para tratar uma doença ou condição, para tratar uma condição de lipodistrofia em um sujeito, para produzir uma molécula de ligação a antígeno biespecífica, e, para administrar uma molécula de ligação a antígeno biespecífica isolada ou composição farmacêutica.
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
BR112020016144A2 (pt) * 2018-02-09 2020-12-15 Nestlé Skin Health Sa Nemolizumabe no tratamento de dermatite atópica com escoriação moderada a grave
US20210024621A1 (en) * 2018-03-16 2021-01-28 National University Corporation Shiga University Of Medical Science Antibody fragment degrading and removing abnormal tdp-43
CN112040980A (zh) * 2018-04-06 2020-12-04 瑞泽恩制药公司 用于治疗代谢功能障碍或低瘦蛋白血症的瘦蛋白受体激动剂抗体
AU2019267050B2 (en) * 2018-05-09 2024-09-12 Good T Cells, Inc. Epitope of regulatory T cell surface antigen and antibody specifically binding thereto
TWI840360B (zh) 2018-05-21 2024-05-01 日商中外製藥股份有限公司 密封於玻璃容器之凍結乾燥的製劑、套組、製造凍結乾燥製劑的方法、防止或減低凍結乾燥製劑的玻璃容器成霧的方法、及容器內面經過硫酸銨處理或ｖｉｓｔ處理之玻璃容器
CN115636141A (zh) 2018-05-28 2023-01-24 中外制药株式会社 填充喷嘴
WO2019235420A1 (ja) 2018-06-04 2019-12-12 中外製薬株式会社 複合体を検出する方法
CN112236166A (zh) * 2018-06-13 2021-01-15 科马布有限公司 用于治疗骨疾病的转铁蛋白受体-2的拮抗剂和激动剂
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
TWI822815B (zh) * 2018-07-14 2023-11-21 財團法人生物技術開發中心 抗-人類ｐｄ-ｌ１之抗體及其用途
PE20211399A1 (es) * 2018-08-01 2021-07-27 Novo Nordisk As Anticuerpos procoagulantes mejorados
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN112912395B (zh) * 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法
SG11202102882YA (en) * 2018-09-28 2021-04-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule comprising altered antibody variable region
BR112021005722A2 (pt) * 2018-09-28 2021-07-06 Chugai Pharmaceutical Co Ltd moléculas de ligação ao antígeno capazes de ligar cd3 e cd137, porém não simultaneamente
WO2020077120A1 (en) * 2018-10-10 2020-04-16 The Board Of Trustees Of The Leland Stanford Junior University BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS
AR123405A1 (es) * 2018-12-21 2022-11-30 23Andme Inc Anticuerpos anti-il-36 y métodos de uso de estos
SI3723858T1 (sl) * 2018-12-21 2022-04-29 Kymab Limited Bispecifično protitelo FIXAXFX s skupno lahko verigo
WO2020136096A1 (en) * 2018-12-29 2020-07-02 Berysol Gmbh Selenium binding protein 1 detection from body fluids for diagnosis of peracute tissue damage
BR112021018627A2 (pt) * 2019-03-21 2021-11-23 Regeneron Pharma Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
AU2020248645A1 (en) * 2019-03-27 2021-10-28 Tigatx, Inc. Engineered IgA antibodies and methods of use
KR20240046282A (ko) * 2019-04-17 2024-04-08 노보 노르디스크 에이/에스 이중 특이적 항체
EP3962936A1 (en) * 2019-05-03 2022-03-09 Singapore Health Services Pte. Ltd. Treatment and prevention of metabolic diseases
AU2020329191A1 (en) * 2019-08-12 2022-03-31 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
KR20220050971A (ko) * 2019-08-27 2022-04-25 엘피사이언스 (쑤저우) 바이오파마, 엘티디. 신규 항-cd39 항체
CN113795510A (zh) * 2019-08-29 2021-12-14 荣昌生物制药(烟台)股份有限公司 抗pd-l1抗体及其应用
EP3798235A1 (en) * 2019-09-24 2021-03-31 Industrial Technology Research Institute Anti-tigit antibodies and methods of use
JP2022550978A (ja) 2019-10-11 2022-12-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 薬剤用量決定デバイスおよび方法
CA3152701A1 (en) 2019-10-11 2021-04-15 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition
WO2021070885A1 (ja) 2019-10-11 2021-04-15 中外製薬株式会社 後天性血友病ａの予防および／または治療に用いられる医薬組成物、および当該医薬組成物を含む製品
US11890353B2 (en) * 2019-10-15 2024-02-06 Northwestern University Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies
KR102575994B1 (ko) * 2019-12-06 2023-09-08 한국원자력연구원 항-tm4sf4 항체 및 이의 용도
CN115052898A (zh) 2020-01-30 2022-09-13 诺和诺德股份有限公司 双特异性因子viii模拟抗体
US20210301010A1 (en) * 2020-03-23 2021-09-30 Medimmune Limited Methods for treating atopic dermatitis and related disorders
EP4132969A4 (en) * 2020-04-07 2024-05-01 Fred Hutchinson Cancer Center ANTI-MESOTHELIN ANTIGEN BINDING MOLECULES AND THEIR USES
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
KR20230005268A (ko) * 2020-04-24 2023-01-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-cd19 항체 및 이의 용도
AU2021263767A1 (en) * 2020-04-30 2022-09-08 Genentech, Inc. KRas specific antibodies and uses thereof
JPWO2021235537A1 (pt) 2020-05-22 2021-11-25
BR112022022235A2 (pt) * 2020-05-22 2023-03-28 Regeneron Pharma Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
AU2021322238A1 (en) * 2020-08-05 2023-03-23 Synthekine, Inc. Compositions and methods related to IL27 receptor binding
MX2023002106A (es) * 2020-08-21 2023-03-15 Genzyme Corp Anticuerpos fgfr3 y metodos de uso.
WO2022094009A1 (en) * 2020-10-30 2022-05-05 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Single domain antibodies to sars-cov-2 nucleocapsid protein
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
US20220257614A1 (en) * 2021-02-16 2022-08-18 New York Medical College Use of 12-lipoxygenase inhibitors in the treatment of covid-19
AU2022241935A1 (en) * 2021-03-22 2023-09-28 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
EP4314075A2 (en) * 2021-03-24 2024-02-07 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
WO2022223771A1 (en) * 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
JPWO2023058723A1 (pt) 2021-10-08 2023-04-13
KR20230130560A (ko) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체의 주 1회 투여 방법
KR20230130558A (ko) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체의 월 1회 투여 방법
KR20230130561A (ko) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법
WO2024008904A2 (en) 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)
JP7459354B2 (ja) 2022-07-08 2024-04-01 ノヴォ ノルディスク アー／エス ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物

Family Cites Families (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5824836B2 (ja) 1974-10-14 1983-05-24 ノウミボウサイコウギヨウ カブシキガイシヤ カサイナドノツウホウソウチ
JPS5334319A (en) 1976-09-12 1978-03-30 Nat Jutaku Kenzai Entrance device of unit residence
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
JPS59162441U (ja) 1983-04-14 1984-10-31 千代田紙業株式会社 吹込口を有する重包包装
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE66249T1 (de) 1984-01-12 1991-08-15 Chiron Corp Hybridom-zellinien und monoklonale antikoerper gegen faktor-viii-c.
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH06104071B2 (ja) 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
JPH0338228Y2 (pt) 1986-09-26 1991-08-13
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
IL89491A0 (en) 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
JPH0646389Y2 (ja) 1989-05-12 1994-11-30 ナショナル住宅産業株式会社 ハンドグリップ取付構造
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE68928946T2 (de) 1989-12-11 1999-10-21 Immunomedics, Inc. Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
TW212184B (pt) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH05184383A (ja) 1990-06-19 1993-07-27 Dainabotsuto Kk 二重特異性抗体
JPH05199894A (ja) 1990-08-20 1993-08-10 Takeda Chem Ind Ltd 二重特異性抗体および抗体含有薬剤
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
DK0628639T3 (da) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
JPH05304992A (ja) 1991-06-20 1993-11-19 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH0767688B2 (ja) 1992-01-21 1995-07-26 近畿コンクリート工業株式会社 Ｐｃコンクリートパネル
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH05203652A (ja) 1992-01-28 1993-08-10 Fuji Photo Film Co Ltd 抗体酵素免疫分析法
JPH05213775A (ja) 1992-02-05 1993-08-24 Otsuka Pharmaceut Co Ltd Ｂｆａ抗体
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
DK0584348T3 (da) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetisk vaccine mod immundefektvirusser
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
EP0660937A1 (en) 1993-07-01 1995-07-05 Dade International Inc. Process for the preparation of factor x depleted plasma
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
CA2194369C (en) 1994-07-11 2004-08-31 Philip E. Thorpe Methods and compositions for the specific coagulation of vasculature
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
ES2384222T3 (es) 1994-10-07 2012-07-02 Chugai Seiyaku Kabushiki Kaisha Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo
CN100350973C (zh) 1994-10-21 2007-11-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
EP1241264A1 (en) 1994-12-02 2002-09-18 Chiron Corporation Monoclonal antibodies to colon cancer antigen
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
WO1996026648A1 (en) 1995-02-28 1996-09-06 The Procter & Gamble Company Preparation of noncarbonated beverage products having superior microbial stability
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
KR100259828B1 (ko) 1995-09-11 2000-06-15 히라타 다다시 인체 인터루킨 5 수용체 알파-사슬에 대한 항체
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
AU720232B2 (en) 1996-07-19 2000-05-25 Amgen, Inc. Analogs of cationic proteins
JPH10165184A (ja) 1996-12-16 1998-06-23 Tosoh Corp 抗体、遺伝子及びキメラ抗体の製法
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US5980893A (en) 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ES2293691T3 (es) 1997-10-03 2008-03-16 Chugai Seiyaku Kabushiki Kaisha Anticuerpo humano natural.
CN1073412C (zh) 1998-03-19 2001-10-24 中国科学院化学研究所 一种高分子微包囊的制备方法
ATE512225T1 (de) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
MXPA01005515A (es) 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1074842A1 (en) 1999-07-21 2001-02-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Catalytic anti-factor VIII allo-antibodies
NL1012907C2 (nl) * 1999-08-25 2001-02-27 Amb It Holding Bv Stelsel voor het bepalen van de positie van een transponder.
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
JP2004505609A (ja) 2000-04-03 2004-02-26 オックスフォード　グリコサイエンシズ（ユーケー）　リミテッド 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用
WO2001082899A2 (en) 2000-05-03 2001-11-08 Mbt Munich Biotechnology Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
WO2002006838A1 (fr) 2000-07-17 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Methode de criblage d'un ligand dote d'une activite biologique
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
AU2002213251B2 (en) 2000-10-16 2007-06-14 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
AU2002210918B2 (en) 2000-10-20 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｖｌａ-1에 대한 항체들
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
PT1411118E (pt) 2001-06-22 2008-12-09 Chugai Pharmaceutical Co Ltd Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
US20030224397A1 (en) 2002-02-11 2003-12-04 Genentech, Inc. Antibody variants with faster antigen association rates
US8030461B2 (en) 2002-04-15 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for constructing scDb libraries
EP1505148B1 (en) 2002-04-26 2009-04-15 Chugai Seiyaku Kabushiki Kaisha Methods of screening for agonistic antibodies
EP1510943A4 (en) 2002-05-31 2007-05-09 Celestar Lexico Sciences Inc INTERACTION PREDICTION DEVICE
JP2004086862A (ja) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
AU2003256266A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
AU2003269456A1 (en) 2002-10-07 2004-04-23 Mempile Inc. Tight focusing method and system
GB0224082D0 (en) 2002-10-16 2002-11-27 Celltech R&D Ltd Biological products
WO2004060919A1 (ja) 2002-12-26 2004-07-22 Chugai Seiyaku Kabushiki Kaisha ヘテロ受容体に対するアゴニスト抗体
JP4477579B2 (ja) 2003-01-21 2010-06-09 中外製薬株式会社 抗体の軽鎖スクリーニング方法
CA2515081A1 (en) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
GB2400851B (en) 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
AU2004242614B2 (en) 2003-05-30 2011-09-22 Merus N.V. Fab library for the preparation of anti vegf and anti rabies virus fabs
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
JP2005101105A (ja) 2003-09-22 2005-04-14 Canon Inc 位置決め装置、露光装置、デバイス製造方法
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP2311945A1 (en) 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies substituting for functional proteins
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
PT1711207E (pt) 2003-12-10 2013-02-13 Medarex Inc Anticorpos alfa interferão e seus usos
EP2865687A1 (en) 2003-12-10 2015-04-29 E. R. Squibb & Sons, L.L.C. IP-10 antibodies and their uses
CA2550996A1 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
PE20051053A1 (es) 2004-01-09 2005-12-12 Pfizer ANTICUERPOS CONTRA MAdCAM
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20060019342A1 (en) 2004-06-25 2006-01-26 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US20080233131A1 (en) 2004-09-14 2008-09-25 Richard John Stebbings Vaccine
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
WO2006065208A1 (en) 2004-12-14 2006-06-22 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP1870458B1 (en) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
CA2603264C (en) * 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
KR101259655B1 (ko) 2005-04-15 2013-04-30 제넨테크, 인크. Ｈｇｆ 베타 사슬 변이체
CA2607281C (en) 2005-05-05 2023-10-03 Duke University Anti-cd19 antibody therapy for autoimmune disease
TW200718780A (en) 2005-06-10 2007-05-16 Chugai Pharmaceutical Co Ltd Sc(Fv)2 site-directed mutant
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
EP1915176A4 (en) 2005-07-15 2008-12-03 Univ Vermont ULTRASENSITIVE IMMUNOASSAY AND ANTIBODIES FOR DETECTION OF BLOOD FACTOR VIII
SI1915397T1 (sl) 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
DK2006381T3 (en) * 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
AU2007255753B2 (en) 2006-06-08 2013-01-17 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
JPWO2008090960A1 (ja) 2007-01-24 2010-05-20 協和発酵キリン株式会社 ガングリオシドｇｍ２に特異的に結合する遺伝子組換え抗体組成物
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
AU2007358045A1 (en) 2007-08-23 2009-02-26 Lfb Biotechnologies Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the C1 domain of factor VIII
HUE029635T2 (en) 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR
SG193868A1 (en) 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
NZ584769A (en) 2007-09-28 2011-09-30 Chugai Pharmaceutical Co Ltd Anti-glypican-3 antibody having improved kinetics in plasma
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN101906160A (zh) 2009-06-05 2010-12-08 苏州泽璟生物制药有限公司 一种抗人凝血因子ⅷ单克隆抗体及其制备方法和用途
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
BR112012017124C1 (pt) 2009-12-25 2021-08-31 Chugai Pharmaceutical Co Ltd Método para produzir e para purificar um multímero polipeptídico
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
CA2791652C (en) 2010-03-02 2018-06-12 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
KR20120138241A (ko) 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체
KR20130018256A (ko) 2010-03-31 2013-02-20 제이에스알 가부시끼가이샤 친화성 크로마토그래피용 충전제
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
JP6022444B2 (ja) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
CA2802072A1 (en) 2010-06-14 2011-12-22 Paion Deutschland Gmbh Treatment of coagulopathy with hyperfibrinolysis
EP2603526A1 (en) 2010-08-13 2013-06-19 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
RU2620071C2 (ru) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
CA2812739A1 (en) 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
CA2839539C (en) * 2011-06-30 2021-06-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
AU2012328322A1 (en) 2011-10-27 2014-06-12 Genmab A/S Production of heterodimeric proteins
KR102168733B1 (ko) 2011-10-31 2020-10-23 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
HRP20211773T1 (hr) 2011-11-04 2022-03-04 Zymeworks Inc. Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
WO2014067011A1 (en) 2012-11-02 2014-05-08 Zymeworks Inc. Crystal structures of heterodimeric fc domains
EP2794905B1 (en) 2011-12-20 2020-04-01 MedImmune, LLC Modified polypeptides for bispecific antibody scaffolds
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
SG11201404481RA (en) 2012-03-08 2014-09-26 Hoffmann La Roche Abeta antibody formulation
JP6273219B2 (ja) 2012-03-13 2018-01-31 ノビミューン エスアー 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
MX363213B (es) 2012-08-13 2019-03-15 Regeneron Pharma Anticuerpos anti-pcsk9 con características de unión dependientes del ph.
TWI609083B (zh) 2012-09-28 2017-12-21 Chugai Pharmaceutical Co Ltd Blood coagulation reaction assessment method
ES2773107T3 (es) 2012-10-05 2020-07-09 Kyowa Kirin Co Ltd Composición de proteína heterodimérica
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
BR112015012385A2 (pt) 2012-11-28 2019-08-27 Zymeworks Inc constructo de polipeptídeo de ligação de antígeno isolado, polinucleotídeo isolado ou conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do constructo, método para tratar um sujeito tendo uma doença ou distúrbio ou câncer ou doença vascular, método para inibir, reduzir ou bloquear um sinal dentro de uma célula, método para obter o constructo, método para preparar o constructo, meio de armazenamento legível por computador, método implementado por computador e método para produzir um constructo de polipeptídeo de ligação de antígeno bi-específico
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
AU2014343636A1 (en) 2013-11-04 2016-06-02 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2015181805A1 (en) 2014-05-28 2015-12-03 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
JP6630036B2 (ja) 2014-09-30 2020-01-15 Jsr株式会社 標的物の精製方法、及び、ミックスモード用担体
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
JP2018123055A (ja) 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
EP3395835B1 (en) 2015-12-25 2021-02-03 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
EP3463451A1 (en) 2016-05-26 2019-04-10 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
SG11201900373WA (en) 2016-07-19 2019-02-27 Ibentrus Inc Bispecific proteins and methods for preparing same
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
CN109661241A (zh) 2016-09-06 2019-04-19 中外制药株式会社 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
UA128389C2 (uk) 2017-09-29 2024-07-03 Чугаі Сейяку Кабусікі Кайся Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт

Also Published As

Publication number Publication date
DK2644698T3 (en) 2018-01-22
HRP20180421T1 (hr) 2018-04-20
KR101962483B1 (ko) 2019-03-29
TW201414835A (zh) 2014-04-16
KR20130102640A (ko) 2013-09-17
JP2021065233A (ja) 2021-04-30
KR101398363B1 (ko) 2014-05-22
EP2644698A4 (en) 2015-07-01
KR20130102113A (ko) 2013-09-16
AU2016203564B2 (en) 2017-11-02
KR20190033644A (ko) 2019-03-29
MX2013005394A (es) 2013-07-29
US20230212315A1 (en) 2023-07-06
CN103298937B (zh) 2016-05-25
PT2644698T (pt) 2018-01-31
BR112013012213A2 (pt) 2020-09-01
LTPA2018507I1 (lt) 2018-06-25
US20220267470A1 (en) 2022-08-25
WO2012067176A1 (ja) 2012-05-24
HUS1800029I1 (hu) 2018-07-30
US20130330345A1 (en) 2013-12-12
RU2534564C1 (ru) 2014-11-27
RU2534347C1 (ru) 2014-11-27
CN105859889B (zh) 2020-01-07
JPWO2012067176A1 (ja) 2014-05-12
TR201802772T4 (tr) 2018-03-21
US20170022293A1 (en) 2017-01-26
US9334331B2 (en) 2016-05-10
JP2017046697A (ja) 2017-03-09
US20140037632A1 (en) 2014-02-06
JP2019129826A (ja) 2019-08-08
AU2011330184B2 (en) 2016-03-10
US20160222129A1 (en) 2016-08-04
US20240059795A1 (en) 2024-02-22
AU2011330184A1 (en) 2013-05-09
LUC00076I2 (en) 2018-07-30
TW201414836A (zh) 2014-04-16
RS57038B1 (sr) 2018-05-31
PL2644698T3 (pl) 2018-06-29
TW201243049A (en) 2012-11-01
CN103298937A (zh) 2013-09-11
MY166429A (en) 2018-06-26
FR18C1031I1 (pt) 2018-08-31
PH12016502073A1 (en) 2018-01-29
US10450381B2 (en) 2019-10-22
JP6710131B2 (ja) 2020-06-17
LTC2644698I2 (lt) 2019-09-10
MX355060B (es) 2018-04-03
JP2022191374A (ja) 2022-12-27
RU2534564C3 (ru) 2019-11-12
TWI452135B (zh) 2014-09-11
KR20130108407A (ko) 2013-10-02
JP6823677B2 (ja) 2021-02-03
EP3318633A1 (en) 2018-05-09
CA2817964A1 (en) 2012-05-24
NL300940I2 (nl) 2018-10-25
US20140370018A1 (en) 2014-12-18
SI2644698T1 (en) 2018-05-31
EP2644698A1 (en) 2013-10-02
FR18C1031I2 (fr) 2020-09-25
JP2013143942A (ja) 2013-07-25
CA2817964C (en) 2018-06-12
NO2018024I1 (no) 2018-07-10
KR101398290B1 (ko) 2014-05-22
JP5246905B1 (ja) 2013-07-24
TWI452136B (zh) 2014-09-11
TWI629355B (zh) 2018-07-11
NO2023034I1 (no) 2023-09-06
CN105859889A (zh) 2016-08-17
TW201631153A (zh) 2016-09-01
RU2013118448A (ru) 2014-10-27
JP6013915B2 (ja) 2016-10-25
AU2016203564A1 (en) 2016-06-16
LT2644698T (lt) 2018-02-26
JP2013150604A (ja) 2013-08-08
RU2620071C2 (ru) 2017-05-22
HUE038305T2 (hu) 2018-10-29
JP5246906B1 (ja) 2013-07-24
EP2644698B1 (en) 2018-01-03
ES2660151T3 (es) 2018-03-21
HK1223379A1 (zh) 2017-07-28
KR102099580B1 (ko) 2020-04-10
US20190315884A1 (en) 2019-10-17
JP2024116410A (ja) 2024-08-27

Similar Documents

Publication Publication Date Title
FR18C1031I1 (pt)
BR112013008959A2 (pt)
BR112012031500A2 (pt)
BR112012029986A2 (pt)
BR112012030039A2 (pt)
BR112012028408A2 (pt)
BR112012026492A2 (pt)
BR112012027808A2 (pt)
BR112012024897A2 (pt)
BR112012025307A2 (pt)
BR112012019354A2 (pt)
BR112012026946A2 (pt)
BR112012017960A2 (pt)
BR112012025482A2 (pt)
BR112013006400A2 (pt)
BR112012031826A2 (pt)
BR112012028186A2 (pt)
BR112012025577A2 (pt)
BR112012023249A2 (pt)
BR112012016456A2 (pt)
BR112012018256A2 (pt)
BR112012027015A2 (pt)
BR112012025308A2 (pt)
BR112012027945A2 (pt)
BR112012024872A2 (pt)